Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized trial of adjuvant SOX with versus without concurrent radiotherapy after D2 gastrectomy for gastric cancer
ChiCTR-TRC-12002919Phase 3Recruiting
- Sponsor
- Department of medical oncology, Cancer Center, West China Hospital, Sichuan University
- Start
- Dec 2012
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tegafur + gimeracil + oteracil and oxaliplatin in gastric cancer (GC) (2 arms), sponsored by Department of medical oncology, Cancer Center, West China Hospital, Sichuan University. Primary endpoint: 3-year disease-free survival. Started Dec 2012; status: recruiting.
02
Drugs
tegafur + gimeracil + oteraciloxaliplatin
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR-TRC-12002919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-12002919.